Onychomed (Terbinafine Hydrochloride)

Terbinafine Hydrochloride, the active ingredient in Onychomed, is an antifungal presented as a 250 mg tablet for oral use. It treats fungal infections of the nail (onychomycosis) in adults and adolescents. GNH USA supplies Onychomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Onychomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Terbinafine is an antifungal agent that acts on dermatophyte infections of the skin, nail and hair. - Onychomycosis: Improves nail appearance and reduces fungal load. - Tinea pedis (athlete’s foot): Relieves scaling and itching. - Tinea corporis (ringworm): Clears skin lesions and prevents spread. - Tinea cruris (jock itch): Reduces erythema and pruritus. - Tinea capitis: Eliminates scalp fungal infection in children. - Seborrheic dermatitis: Decreases flaking and redness.

Terbinafine is generally well‑tolerated, but adverse reactions can occur.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort. - Skin reactions: mild rash or pruritus. - Headache: transient and usually mild. - Taste disturbance: temporary loss of taste sensation. - Elevated liver enzymes: mild, reversible changes.

Serious or Rare Side Effects: - Hepatotoxicity: signs of liver injury such as jaundice. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood disorders: neutropenia or agranulocytosis. - Peripheral neuropathy: tingling or numbness in extremities. - Anaphylaxis: acute allergic reaction requiring emergency care.

Before prescribing Terbinafine, clinicians should assess liver function and potential drug interactions.

- Liver function monitoring: baseline and periodic tests recommended. - Alcohol consumption: limit intake to reduce hepatic stress. - Pregnancy and lactation: avoid unless benefits outweigh risks. - Age considerations: use caution in elderly patients with comorbidities. - Concomitant medications: review for CYP2D6 substrates. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Terbinafine may affect the metabolism of several co‑administered medicines.

Major Interactions (Avoid): - Cimetidine: may increase terbinafine plasma levels. - Itraconazole: combined use raises risk of hepatotoxicity. - Rifampicin: reduces terbinafine effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect. - Oral contraceptives: possible reduction in efficacy. - Antidepressants (SSRIs): monitor for QT‑prolongation. - Antiretrovirals (protease inhibitors): adjust dosing if needed. - Statins: observe liver function during combined therapy.